氨溴索口服液联合阿奇霉素治疗儿童支原体肺炎疗效观察

目的观察氨溴索口服液联合阿奇霉素治疗儿童支原体肺炎的疗效。方法选取2009年12月～2012年12月我院住院接受治疗的儿童支原体肺炎患儿62例进行回顾性分析；其中应用氨溴索口服液联合阿奇霉素治疗的32例患儿，设立为观察组，余30例患儿应用阿奇霉素治疗，设立为对照组，比较两组治疗患儿退热时间、咳嗽、肺部哕音消失时间及住院时间，并依据疗效评价标准比较两组治疗后的治愈率及总有效率。结果观察组患儿治疗7d后，退热时间快、咳嗽、肺部哕音消失时间均快于对照组，且观察组住院时间也明显短于对照组，差异具有显著性（P〈0．05）。观察组32例患儿治疗后治愈率达50％，总有效率达96．88％，对照组30例患儿治疗后治愈率达40．00％，总有效率80．00％，两组治愈率比较未见明显差异，两组总有效率比较，差异具有显著性（P〈0．05）。观察组出现恶心、呕吐2例，腹痛1例，未出现腹泻。对照组患儿治疗期间出现恶心2例，腹泻1例，余未见明显异常。结论氨溴索口服液联合阿奇霉素治疗儿童支原体肺炎可以提高临床疗效，安全性好，值得推广和应用。

Ambroxol oral azithromycin in treatment of children with mycoplasma pneumonia

Objective To observe the effect of ambroxol oral azithromycin treatment of children with mycoplasma pneumonia. Methods From December 2009 to December 2012 in our hospital,62 cases hospitalized children my- coplasma pneumonia in children; Ambroxol oral and azithromycin in treatment of 32 patients, the establishment of the observation group, more than 30 cases of children in threatment of azithromycin, established as control group. The fever, cough, pulmonary rales disappeared time and length of stay were compared in children with MP, and based on response evaluation criteria in two groups, the efficiency were compared after treatment. Results The treatment of chil- dren with fast fever, cough, pulmonary rales disappeared faster than the control group,observation group hospital stay was significantly shorter than the control group. Observation group 32 patients after treatment markedly effective rate was 50%, total effective rate was 96.88%, markedly effective rate was 40.00% in the control group of 30 patients after treatment, the total effective rate was 80.00%, the two groups had significantly more efficient, the difference of total ef- ficiency comparison was significant between the two groups （P〈0.05）. The observation group nausea and vomiting in 2 cases, 1 case of abdominal pain, diarrhea does not appear. Control group during treatment in children with nausea in 2 cases, 1 case of diarrhea, no obvious abnormalities. Conclusion Ambroxol oral and azithromycin treatment of children with myeoplasma pneumonia can improve the clinical efficacy, safety, worthy of promotion and application.